Ponte al día con Fierce Pharma...

Like several of its rivals, Sanofi-Aventis is expected to post a 3.5 percent rise in fourth-quarter adjusted net profit next week but give a prudent forecast for 2010 when battles with generic rivals will intensify. Story

Surging sales in emerging markets helped GlaxoSmithKline compensate for declining revenues in the U.S.; CEO Andrew Witty, the architect of GSK's emerging-markets focus, said the growth shows that strategy is working. Report

Glaxo also said it will stop research into new antidepressants and focus on diseases for which it believes it can develop more valuable drugs--a major shift for a company that developed some of the biggest-selling antidepressants of the past 20 years. Report | Item

Two and a half years after the papers were signed and the letterhead changed--and at the beginning of a year when the combined company had planned to deliver on some of its first milestones--some analysts say MedImmune has not measured up to the purchase price AstraZeneca paid. Story

During the Pfizer analyst call, executives talked about their strategies for winning market share in China--strategies that look a lot like its U.S. tactics back when it was fielding an enormous sales force, the Health Blog notes. Story